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Abstract 
The emerging resistance of tumor cells against methotrexate (MTX) is one of the major 
limitations of the MTX treatment of tumorous diseases. The disturbance in the 
polyglutamation which is a main step in the mechanism of methotrexate action is often the 
reason of the resistance. Delivery of polyglutamylated MTX into cells may evade the 
mechanisms that are responsible for drug resistance. In this study conjugates of methotrexate 
and its pentaglutamylated derivatives with cell-penetrating peptides – penetratin and 
octaarginine – were investigated. The cellular-uptake and in vitro cytostatic activity of 
conjugates were examined on breast cancer cell cultures (MDA-MB-231 as resistant and 
MCF-7 as sensitive cell culture). These cell cultures showed very different behaviour towards 
the conjugates. Although the presence of pentaglutamyl moiety significantly decreased the 
internalisation of conjugates, some of them were significantly active in vitro. All of the 
conjugates were able to penetrate in some extent into both cell types, but only the conjugates 
of penetratin showed in vitro cytostatic activity. The most effective conjugates were the 
MTX-Glu5-Penetratin(desMet) and MTX-Glu5-GFLG-Penetratin(desMet). The latter was 
effective on both cell cultures while the former was active only on the resistant tumor cells. 
Our results suggest that the translocation of polyglutamylated MTX may be a new way to 
treat sensitive and more importantly resistant tumors. While both penetratin and octaarginine 
peptides were successfully used to deliver several kinds of cargos earlier in our case the 
activity of penetratin conjugates was more pronounced. 
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Introduction 
Methotrexate (4-amino-10-methylfolic acid, MTX) was the first antimetabolite used in the 
treatment of tumorous diseases from the 1950s. As an effective anticancer drug it is clinically 
used to treat childhood acute lymphoblastic leukemia and a number of other hematologic 
malignancies [1]. Methotrexate, belonging to the antifolate antimetabolite family, can be 
internalised into cells by specific transporters - the membrane-bound reduced folate carrier 
(RFC-1) and/or folate-binding proteins (folate receptors Fr, FR and FR) [2]. Inside the 
cell sequential addition of Glu moiety/moieties occurs by the enzyme folylpolyglutamate 
synthetase (FPGS) [3-5]. Polyglutamylated MTX exhibiting higher affinity to folate-
metabolizing enzymes play crucial role in the metabolism of folic acid and disturb the 
biosynthesis of thymidine and purine, inhibit the synthesis of DNA and could lead to cell 
death. 
During the polyglutamation 5-8 glutamic acid residues are coupled to the MTX via amide 
linkage forming γ-peptide bonds. The MTX is a poor substrate of the FPGS which catalyses 
the glutamic acid attachment and its binding competes with intracellular folates [6]. The 
polyglutamylated forms of MTX can inhibit the dihydrofolate reductase and timidylate 
synthase enzymes. The presence of the polyglutamyl moiety essentially prevents the efflux of 
MTX from the cell because derivatives containing more than three glutamic acid residues are 
not substrates of multidrug resistance protein (MRP 3) [7] and of the folate transporter 
systems [8]. Thus the polyglutamation is a very important process in the action of MTX. The 
concentration of polyglutamylated MTX in the cytosol is modulated by the activity of FPGS 
and of the enzyme -glutamyl hydrolase (GGH), catalysing the removal of Glu residues 
[9,10]. Therefore, the presence of polyglutamylated MTX derivatives depends on the balance 
of glutamic acid attachment and removal. 
Although several second and third generation antifolates have been developed for clinical use, 
the main drawback is the development of the evolving drug resistance. There are various 
processes which are responsible for the drug resistance: i) decreased cellular uptake caused by 
the malfunction of folate transporters [11]; ii) increased efflux related to the overexpression of 
multidrug resistance transporters [12]; and/or iii) decreased level of polyglutamation due to 
inactivation or decreased activation of respective enzymes that take part in these processes 
[13]. The drug resistance can be intrinsic or acquired. Some studies showed that the defect in 
the polyglutamation can result in the intrinsic drug resistance [14,15]. Therefore the 
intracellular delivery of polyglutamylated MTX may provide an effective antitumor drug 
against resistant tumor cells as well. 
Polyglutamylated MTX derivatives are very hydrophilic, and they are not substrates of folate 
transporter systems (RFC-1 and/or FRs) delivering folates into the cells. Consequently, these 
compounds are not able to enter through the cell membrane. This disadvantage may be 
overcome by using cell-penetrating peptides (CPPs). CPPs are short oligopeptides (natural 
and/or of synthetic origin) with cell internalisation capability. Among the first peptides 
discovered, derivatives from proteins: HIV-1 Tat [16,17] and Antennapedia protein of 
Drosophila could be mentioned [18]. These oligopeptides are able to penetrate across the cell 
membrane even in the presence of various, covalently attached cargos (e.g. peptides, peptide-
nucleic acids, oligonucleotides) [19]. 
For targeted delivery into sensitive and/or resistant tumor cells MTX or pemetrexed [20] has 
been conjugated to protein [21], peptides including CPP [22-25], polymeric polypeptides [26], 
dendrimers [27,28] and oligosaccharides [29].  
In spite of the potency of polyglutamylated MTX as effective drug against resistant tumors 
only few studies were reported on conjugates with this molecule. An early paper described 
conjugates in which MTX with different length of polyglutamyl chains were attached to 
polymeric polylysine (average M = 27000 and 52000) [30]. In these conjugates the 
polyglutamylated MTX was coupled via amide bond between the /-carboxylic group of 
glutamic acids and -amino group of lysine side chains. Since the unprotected form was used 
in the conjugation reaction the exact structure of the conjugates (the carboxylic group 
involved in the formation of the amide bond) is unknown. The number of MTX attached to 
the polymer was between 2 and 11. The conjugates showed inhibitory activity of sensitive 
(H35) and MTX transport resistant (H35R) strains of hepatoma cells. In a recent study the 
polyglutamylated forms of MTX were conjugated with sequence-defined 
oligo(ethanamino)amide [31]. These compounds and the free MTX exhibited similar activity 
against human cervix carcinoma KB cells in vitro. 
Based on our promising results on cell penetrating peptide - antitumor drug (daunomycin, 
vinblastine [32,33]) or enzyme activator/substrate peptide [34,35] conjugates our aim was to 
study the cell-penetrating peptide concept to deliver pentaglutamylated methotrexate into 
tumor cells. Here we describe the synthesis and characterization of a novel set of conjugates 
in which pentaglutamylated MTX is covalently attached to the N-terminal of cell-penetrating 
peptides via peptide bond. Two conjugate families are reported here with two different types 
of CPPs (octaarginine or modified penetratin) possessing different mechanisms of uptake. The 
cytostatic effect as well as cellular uptake properties of conjugates were studied on sensitive 
and resistant breast tumor cell lines in vitro. Data collected were comparatively analysed with 
those obtained with MTX-conjugates without pentaglutamyl moiety as well. We observed that 
the presence of penetratin(desMet) highly influenced the activity of pentaglutamylated MTX 
on resistant breast cancer cells even in comparison with the MTX-conjugate, but not on MCF-
7 cells. Interestingly, no in vitro cytotoxic effect was documented with conjugate containing 
Arg8 as CPP. Our results show that the insertion of an enzyme labile spacer (GFLG) between 
pentaglutamylated MTX and penetratin(desMet) could maintain (MDA-MB-231) or increase 
(MCF-7 cell) the activity of the conjugate as well. 
Materials and Methods 
All amino acid derivatives, N,N'-diisopropylcarbodiimide (DIC) and Rink-amide MBHA resin 
were purchased from IRIS Biotech GmbH (Marktredwitz, Germany). N,N-
diisopropylethylamine (DIEA), 1.8-diazabicyclo[5.4.0]undec-7-ene (DBU), thioanisole, 1,2-
ethandithiol (EDT) were FLUKA (Buchs, Switzerland), while 1-hydroxybenzotriazole 
(HOBt), trifluoroacetic acid (TFA) and phenol were Sigma Aldrich (Budapest, Hungary) 
products. Solvents for synthesis and purification were obtained from Molar Chemicals Ltd 
(Budapest, Hungary). Carboxyfluorescein (cf) and all other chemicals used in biological 
experiments were purchased from Sigma Aldrich (Hungary). Buffers were prepared with 
distilled water. 
 Synthesis of peptides and peptide-conjugates 
The conjugates were built up by solid-phase peptide synthesis on Rink amide MBHA resin 
using Fmoc/
t
Bu strategy. The side chain of amino acids were protected by 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl group (Pbf, in Arg), by trityl (Trt, in Asn, Gln), by 
tert-butyl group (
t
Bu, in Glu) and by tert-butyloxycarbonyl group (Boc, in Lys). The N-
terminal Fmoc protecting group was removed with 2% piperidine in the presence of 2% 1.8-
diazabicyclo[5.4.0]undec-7-ene (DBU) in DMF (2+2+5+10 min). This reagent was removed 
by washing with DMF (8x0.5 min). In the coupling reaction, amino acid derivatives, which 
were used in 3 molar excess to the resin capacity, were activated by N,N'-
diisopropylcarbodiimide (DIC) and 1-hydroxybenzotriazole (HOBt) dissolved in DMF. The 
reaction proceeded at RT for 60 min. Then, the resin was washed with DMF (2x0.5 min) and 
dichloromethane (DCM) (3x0.5 min). Ninhydrin assay was used to monitor the efficiency of 
the coupling reaction [36]. After the removal of the terminal N
α
-Fmoc group, methotrexate 
(MTX) or 5(6)-carboxyfluorescein (cf) were attached to the peptide using the HOBt-DIC 
coupling reagents. The free compounds were obtained by cleavage from the resin with 10 mL 
TFA containing 0.75 g phenol, 0.5 mL distilled water, 0.5 mL thioanisole and 0.25 mL 1,2-
ethandithiol (EDT) as scavengers. Crude products were precipitated by dry diethyl-ether, 
dissolved in 10% acetic acid and freeze-dried. The crude peptide was purified by RP-HPLC as 
described below. The purified compounds were characterized by analytical RP-HPLC and 
ESI-MS (Table 1). The purity of the compounds was higher than 95 %. 
 
RP-HPLC 
Analytical RP-HPLC was performed on a Knauer (Herbert Knauer GmbH, Berlin, Germany) 
HPLC system using a Phenomenex Jupiter C18 column (250x4.6mm I.D.) with 5 µm silica 
(300 Å pore size) (Torrance, CA USA) as a stationary phase. Linear gradient elution (0 min 
0% B; 5 min 0% B; 50 min 90% B) with eluent A (0.1% TFA in water) and eluent B (0.1% 
TFA in acetonitrile-water (80:20, V/V)) was used at a flow rate of 1 mL/min at ambient 
temperature. Peaks were detected at λ = 220 nm. The samples were dissolved in eluent B. In 
the other cases Exformma (Exformma Technology (ASIA) Co., Ltd, Hong Kong, China) 
HPLC system was used. The column was Agilent Zorbax SB-C18 4.6mmx150mm, 100Å. 
The applied linear gradient elution was 0 min 0% B, 2 min 0% B, 22 min 90% B with 1 
mL/min flow rate. The detection was carried on at λ = 220 nm. 
The crude products were purified on a semi-preparative Phenomenex Jupiter C18 column 
(250x10mm I.D.) with 10 µm silica (300 Å pore size) (Torrance, CA, USA). Flow rate was 4 
mL/min. Linear gradient elution was applied. The samples for purification were dissolved in 
eluent A containing few percent eluent B. 
 
Mass Spectrometry 
The molecular mass of peptides as well as conjugates was determined by ESI-MS. 
Electrospray ionization mass spectrometric analysis was performed on a Bruker Daltonics 
Esquire 3000 plus (Germany) ion trap mass spectrometer. The samples were dissolved in 
acetonitrile–water (50:50, V/V), containing 0.1% acetic acid. Samples were analyzed by 
direct injection using a syringe pump. Instrumental parameters were the following: capillary 
voltage: 4 kV, nebulizer gas: 10 psi, dry gas: 4 L/min, heated capillary temperature: 250 °C. 
 
Cell cultures for in vitro studies 
MCF-7 (ATCC: HTB-22) human breast adenocarcinoma [37] and MDA-MB-231 (ATCC: 
HTB-26) human triple negative breast adenocarcinoma [38] cells were used for the analysis of 
the in vitro cytostatic effect of MTX containing conjugates and controls (MTX, Arg8 and 
penetratin) and also for the investigation of the cellular uptake of carboxyfluorescein labelled 
compounds. MCF-7 cells were maintained in DMEM supplemented with 10% heat-
inactivated fetal calf serum (FCS), non-essential amino acids (NEAA), pyruvate (1 mM), L-
Gln (2 mM) and gentamicin (160 µg/mL). MDA-MB-231 cells were cultured in RPMI-1640 
supplemented with 10% FCS, L-Gln (2 mM) and gentamicin (16 µg/mL). Cells were 
maintained in plastic tissue culture dishes at 37°C with a humidified atmosphere containing 
5% CO2 / 95% air. 
 
Determination of the in vitro cellular uptake profile by flow cytometry 
MCF-7 and MDA-MB-231 cells were cultured as described above. In order to study the 
cellular uptake of fluorescently labelled compounds, 10
5
 cells per well were plated on 24-well 
plates. After 24 h incubation at 37 °C, cells were treated with the compounds in serum-free 
medium for 90 min. The cellular uptake was analysed at 1, 5 and 10 µM concentrations. Cells 
treated with serum-free medium for 90 min were used as negative control. After incubation, 
the solutions of conjugates were removed from the cells and the cells were treated with 100 
µL trypsin for 10 min. The activity of trypsin was terminated by the addition of 900 µL HPMI 
(glucose, NaHCO3, NaCl, HEPES, KCl, MgCl2, CaCl2, Na2HPO4·2H2O) containing 10% fetal 
calf serum, and the cells were moved from the plate to FACS-tubes. Cells were centrifuged at 
216 g at 4°C for 5 min and the supernatant was removed. Cells were re-suspended in 500 µL 
HPMI. The fluorescence intensity of cells was monitored by flow cytometry (BD LSR II, BD 
Bioscience, San Jose, CA). Data were analyzed with FACSDiVa 5.0 software. 
 
Analysis of the in vitro cytostatic activity of the conjugates 
The cells were grown to confluency and were plated into 96-well plate with initial cell 
number of 5·103 per well. After 24 h incubation at 37 °C, cells were treated with the 
compounds at 1.28·10-3-100 µM concentration range for 3 h in 200 μL final volume. Control 
cells were treated with serum free medium at 37 °C for 3 h. After incubation the cells were 
washed twice with serum free medium. For the analysis of the in vitro cytostatic effect, cells 
were cultured for an additional 72 h in serum containing medium. On day 4, MTT assay 
[39,40] was carried out in order to determine the IC50 values of the compounds. Briefly, 45 μL 
of MTT solution was added to each well (2 mg/mL, dissolved in serum-free medium). 
Following the 4 h incubation, plates were centrifuged at 900 g for 5 min, and the supernatant 
was removed. The precipitated purple crystals were dissolved in 100 μL DMSO and the 
absorbance was determined at λ = 540 nm and 620 nm using ELISA plate reader (iEMS 
Reader, Labsystems, Finland). The percent of cytostasis was calculated using the following 
equation: Cytostatic effect(%) = [1 – (ODtreated/ODcontrol)] x100; where ODtreated and ODcontrol 
correspond to the optical densities of the treated and the untreated control cells, respectively. 
In each case three independent experiments were carried out with 4 parallel measurements. 
The 50% inhibitory concentration (IC50) values were determined from the dose-response 
curves. The curves were defined using MicrocalTM Origin (version 9.2) software: cytostasis 
was plotted as a function of concentration, fitted to a sigmoidal curve, and based on this 
curve, the IC50 value was determined. IC50 represents the concentration of a compound 
required for 50% inhibition in vitro and expressed as micromolar units. 
 
Results 
 
After the internalisation MTX typically undergoes polyglutamation [3-5]. These derivatives 
(MTX-(Glu)n where n = 5 to 8) are very important to maintain the effective intracellular 
concentration. Alteration of the homeostasis of the polyglutamylated MTX forms often results 
in the development of drug resistance [13]. For this study we have selected the 
pentaglutamylated derivative (MTX-Glu5) considering that this compound is not a substrate of 
folate transport systems. We have examined the effect of the pentaglutamylated derivative 
(MTX-Glu5) on the cell viability as well as on the uptake properties of two different tumor 
cell cultures. For intracellular delivery its conjugates with cell-penetrating peptides were also 
synthesised, since - due to its negative charges - this methotrexate derivative is not able to 
penetrate across the cell-membrane.  
 
Synthesis of the conjugates 
The different cell-penetrating peptides could have very diverse internalisation mechanisms 
and thus have high influence on the intracellular fate of the covalently attached cargo moiety. 
Although both octaarginine and penetratin are positively charged with several arginine 
residues in the sequence, based on the characteristics of their internalisation, the two peptides 
belong to different classes of cell-penetrating peptides [41]; penetratin is secondary 
amphipathic [42], while octaarginine is non-amphipathic cell-penetrating peptide [43]. For 
studying whether the difference between the two CPP’s has any effect on in vitro cytostatic 
activity, MTX-conjugates of both peptides were prepared. Since methionine in the penetratin 
sequence could be oxidized under various conditions and might decrease the stability of 
conjugates, penetratin derivative without methionine (RQIKIWFQNRRKWKK 
(Penetratin(desMet))) was produced. Earlier studies [44] as well as our own experience (data 
is not shown) proved that this Met residue can be removed from the sequence without 
decreasing the internalisation ability. 
During the intracellular attachment of polyglutamyl chain γ-peptide bond formed between the 
glutamic acids. However, the cell has also an apparatus to remove this chain from MTX 
[9,10]. Therefore to avoid the decomposition of our MTX derivative by gamma-glutamyl 
hydrolase, the glutamic acid residues were connected with their α-carboxyl group. 
The conjugates of MTX and MTX-Glu5 (Figure 1) with cell-penetrating peptide were 
synthesised by solid phase peptide synthesis using standard Fmoc/
t
Bu strategy. 
 
Figure 1 The structure of MTX (A) and MTX-Glu5 (B) containing CPP-conjugates 
 
First the cell-penetrating peptides with or without pentaglutamyl moiety at their N-terminus 
were built up and MTX was attached to the free N-terminal amino group of peptides using 
DIC and HOBt coupling reagents. Then the conjugates were cleaved from the resin by TFA 
cleavage mixture and were purified by RP-HPLC as described in the Experimental section. 
The characterisation of conjugates was performed by analytical RP-HPLC and ESI-MS (Table 
1). During the purification only one peak was isolated with the correct molecular mass. As the 
MTX contains two carboxyl groups and none of them was protected, the formation of two 
main isomers could be expected during the synthesis of MTX-conjugates. Besides this the 
racemisation of glutamic acid residue in the MTX molecule may also occur, the D-isomers 
might be also present in the mixture. Based on earlier results using the same coupling strategy 
but different peptide component, MTX mainly coupled via its γ-carboxyl group in these 
circumstances [22]. Thus we could isolate the mixture of isomer conjugates containing mainly 
γ-peptide bond between the MTX and the peptides. For the cellular uptake studies 
fluorescence labelled conjugates were also prepared. These derivatives were synthesised as 
MTX conjugates, but cf was attached instead of MTX. 
Since we know little about the fate of internalised conjugates, and about the potential release 
of MTX and MTX-Glu5, we have prepared conjugates with a tetrapeptide spacer (GFLG) 
cleavable by a lysosomal enzyme cathepsin B inserted between the cell-penetrating peptide 
and drug component. The cytostatic as well as uptake properties of these compounds were 
also studied. 
Table 1. Chemical characteristics of peptides and peptide-conjugates 
 
Rt (min) ESI-MS
c
 
Compounds 
 Mcal. Mmeas. 
Arg8* 10.3
b
 1266.5 1266.3 
Penetratin* 12.9
b
 2245.7 2246.2 
Mtx-Arg8 21.2
a
 1702.6 1703.7 
Mtx-Penetratin(desMet)* 24.5
a
 2251.0 2251.4 
Mtx-Glu5-Arg8 21.9
a
 2348.5 2349.0 
Mtx-Glu5-Penetratin(desMet) 25.3
a
 3196.6 3197.1 
Mtx-GFLG-Arg8 12.6
b
 2077.4 2077.8 
Mtx-GFLG-Penetratin(desMet) 14.1
b
 2925.4 2925.9 
Mtx-Glu5-GFLG-Arg8 12.4
b
 2722.9 2723.3 
Mtx-Glu5-GFLG-Penetratin(desMet) 14.1
b
 3571.0 3570.9 
cf-Arg8 11.6
b
 1624.8 1625.4 
cf-Penetratin(desMet) 14.1
b
 2472.9 2473.2 
cf-Glu5-Arg8 22.9
a
 2270.4 2270.7 
cf-Glu5-Penetratin(desMet) 27.8
a
 3118.4 3119.4 
cf-GFLG-Penetratin(desMet) 15.9
b
 2847.3 2846.9 
cf-Glu5-GFLG-Penetratin(desMet) 15.0
b
 3492.9 3492.8 
* Penetratin: RQIKIWFQNRRMKWKK, Arg8: RRRRRRRR, Penetratin(desMet): RQIKIWFQNRRKWKK 
The purity of the compounds was higher than 95 %. 
a 
RP-HPLC retention time value. Column: Phenomenex Luna C18(2) 5 µM, 250x4.6 mm, 100 Å. Linear gradient 
elution: 0 min 0% B; 5 min 0% B; 50 min 90% B with eluent A (0.1% TFA in water) and eluent B (0.1% TFA in 
acetonitrile-water (80:20, V/V)) were used at a flow rate of 1 mL/min at ambient temperature. Peaks were 
detected at λ = 220 nm. 
b
 Column: Agilent Zorbax SB-C18 4.6x150mm, 100Å; Gradient: 0 min 0% B, 2 min 0% B, 22 min 90% B; Flow 
rate:1mL/min; RT, λ=220 nm. 
c 
ESI-MS analysis was carried out on a Bruker Esquire 3000 plus equipment (Germany). The sample was 
dissolved in acetonitrile-water (50:50, V/V), 0.1% acetic acid. 
 
In vitro cytostatic effect of the conjugates 
The in vitro cytostatic activity of MTX-conjugates was examined on two tumor cell lines, 
MCF-7 human breast adenocarcinoma and MDA-MB-231 human triple negative breast 
adenocarcinoma cell lines (Table 2). The main difference between these two cell cultures is 
their receptor status. MCF-7 cells express oestrogen and progesterone receptors, but MDA-
MB-231 cells are oestrogen, progesterone and HER2 receptor negative (called triple negative) 
cells [45]. This different receptor status could cause significant differences in the therapeutic 
responses to various drugs, like in case of MTX. Considering that MCF-7 cells are sensitive to 
MTX treatment, while MDA-MB-231 cells are MTX resistant, these two cell cultures were 
selected as models for our in vitro experiments. It is important to note that the drug resistance 
of MDA-MB-231 cells is due to the lack of reduced folate carrier [46]. 
On MCF-7 cells the free MTX was highly active with IC50 = 0.8 µM, while the free cell-
penetrating peptides, as expected exhibited no activity in the concentration range studied here 
(IC50 > 100 µM). Among the two MTX conjugates only the MTX-Penetratin(desMet) showed 
some moderate activity (IC50 = 40.2 µM), while the octaarginine conjugate was completely 
inefficient. The conjugates of MTX-Glu5 were fully inactive. The influence of enzyme labile 
spacer (GFLG) was also studied. The presence of the GFLG tetrapeptide spacer both in the 
Arg8 and penetratin(desMet) conjugates of MTX increased the activity (IC50 =31.3µM for 
MTX-GFLG-Arg8 and IC50 = 13.9 µM for MTX-GFLG-Penetratin(desMet)). In case of 
MTX-Glu5 conjugates the presence of the spacer resulted in higher activity only in case of 
MTX-Glu5-GFLG-Penetratin(desMet) (IC50= 0.3 µM), while the octaarginine conjugate was 
ineffective. 
 
Table 2 In vitro cytostatic activity of MTX-conjugates on tumor cells 
 
IC50 (sd) (µM)
a
 
 Compound  
MDA-MB-231 MCF-7 
Mtx > 100 0.8 (0.3) 
Arg8 > 100 > 100 
Penetratin > 100 > 100 
Mtx-Arg8 ~ 100 > 100 
Mtx-Penetratin(desMet) 12.9 (4.0) 40.2 (14.4) 
Mtx-Glu5-Arg8 > 100 > 100 
Mtx-Glu5-Penetratin(desMet) 0.1 (0.1) >100 
Mtx-GFLG-Arg8 19.1 (3.7) 31.3 (9.6) 
Mtx-GFLG-Penetratin(desMet)  5.5 (0.5) 13.9 (0.5) 
Mtx-Glu5-GFLG-Arg8 ~100 > 100 
Mtx-Glu5-GFLG-Penetratin(desMet)   0.4 (0.1)     0.3 (0.1) 
a
 The cells were incubated with the compound for 3 h, after cultured in serum-containing 
medium for 3 days. The IC50 values were determined by MTT assay as described in the 
text. Standard deviation values (sd) are also presented. 
 
In the agreement with the literature [46], free MTX was ineffective against the resistant 
MDA-MB-231 cells (IC50 > 100 µM) as compared to the MCF-7 cells (Table 2). The cell-
penetrating peptides had also no effect on these cells in the applied concentration range (IC50 
> 100 µM). Although the cell-penetrating peptide can transport the covalently attached MTX 
very effectively (see the next section), only the MTX-Penetratin(desMet) had low activity 
(IC50 = 12.9 µM). Incorporation of the pentapeptide of Glu resulted in a highly cytostatic 
compound (IC50 = 0.1 µM). In contrast, similar conjugate with octaarginine did not improve 
the cytostaic effect against the resistant MDA-MB-231 cells (IC50 = 100 µM for both MTX-
Arg8 and MTX-Glu5-Arg8). Incorporation of the GFLG tetrapeptide spacer between the cell-
penetrating peptide and MTX increased the activity of both conjugates. The presence of this 
tetrapeptide did not elevate the activity of MTX-Glu5 conjugates. Based on the in vitro 
cytostatic effect on MDA-MB-231 cells the following order could be established among 
conjugates containing penetratin(desMet): MTX-Glu5-Penetratin(desMet) (IC50 = 0.1 µM) > 
MTX-Glu5-GFLG-Penetratin(desMet) (IC50 = 0.4 µM) > MTX-GFLG-Penetratin(desMet) 
(IC50 = 5.5 µM) > MTX-Penetratin(desMet) (IC50 = 12.9 µM). 
 
Internalisation of the conjugates 
Based on the in vitro cytostatic activity of the conjugates, cellular uptake profile of some 
conjugates was investigated by flow cytometry. Considering difficulties in measuring the 
cellular uptake based on the spectroscopic properties of MTX we have prepared conjugates in 
which the drug was replaced by 5(6)-carboxyfluorescein (cf). The cellular uptake profile of 
these compounds was studied and accepted as an approximation for the uptake of the relevant 
MTX-Glu5-CPP or MTX-CPP conjugates.  
First, we were interested in studying the uptake properties of conjugates containing five 
glutamic acid residues by MTX sensitive and resistant cells. MCF-7 and MDA-MB-231 cells 
were treated with the solution of cf labelled compounds using in the concentration range of 1 
to 10 M at RT for 90 min. After washing and trypsin treatment the fluorescence intensity of 
the cells was measured by flow cytometry (Figure 2). All conjugates were able to penetrate 
into the cells and the amount of internalised conjugates was increased by the elevated 
concentration. Based on the fluorescence intensity of the cells the internalisation of cf labelled 
octaarginine was higher than that of cf-Penetratin(desMet) on both cell lines. The intracellular 
amount of octaarginine was significantly increased by the concentration (mean fluorescence 
of MCF-7 cells: 975 (1 µM) < 8669 (5 µM) < 52928 (10 µM), Figure 2A). The cellular-
uptake of penetratin(desMet) also showed growing value with the concentrations, but the rise 
was lower (mean fluorescence of MCF-7 cells: 1728 (1 µM) < 7361 (5 µM) <12310 (10 µM), 
Figure 2A). The internalisation of octaarginine was more pronounced on MDA-MB-231 cells 
while the penetratin had similar cellular uptake on both cell lines. 
 
 
 
Figure 2 Cellular-uptake profile of fluorescently labelled conjugates by different cells A) 
MCF-7 and B) MDA-MB-231 cells were treated with the solution of the conjugates (1, 5 and 
10 µM) for 90 min. The fluorescence intensity of the cells was determined by flow cytometry 
after trypsin treatment. 
 
The presence of pentaglutamyl moiety significantly reduced the cellular uptake of the cell-
penetrating peptides. This reduction was the highest in case of octaarginine on both cell 
cultures. The fluorescence intensity decreased below the 10% of the non-glutamylated form. 
In case of penetratin(desMet) the reduction was lower and the pentaglutamylated 
penetratin(desMet) could be internalised more efficiently than the octaarginine derivative. Not 
only the fluorescence intensity, but also the number of fluorescence positive cells was 
decreased. At 1 µM concentration only a few percent of the cells engulfed the 
pentaglutamylated conjugates (data is not shown).  
We also studied the effect of tetrapeptide spacer on the internalisation of penetratin(desMet) 
derivatives. Incorporation of GFLG between the pentaglutamyl moiety and the 
penetratin(desMet) increased significantly the cellular uptake, but it was still lower in 
comparison with the free penetratin(desMet). 
 
Discussion 
The MTX is an active clinically used antitumor drug. Unfortunately tumor cells may become 
resistant against it due to the development of several potential processes. Two of these are in 
relation with the inadequate accumulation of MTX in the cytosol caused by the decreased 
influx or increased efflux and the lack of polyglutamation. In case of sensitive cells the MTX 
influx is adequate to achieve the proper intracellular concentration and the drug could inhibit 
the proliferation (for example MCF-7 cells; Table 2). If this influx is insufficient drug 
resistance could develop (for example MDA-MB-231 cells; Table 2). The accumulation of 
MTX in sensitive or resistant cells can be enhanced for example by using delivery vehicle 
(peptides, polymers, nanoparticles) or in the absence of polyglutamation mechanism by 
intracellular targeting of polyglutamylated MTX. Among others, two main steps could 
influence the activity of free and conjugated MTX derivative: internalisation across the cell-
membrane, and the interaction with the target enzymes.  
In our systematic study we compared the in vitro antitumor effect of new cell-penetrating 
conjugates of MTX and MTX-Glu5. Two cell-penetrating peptides were applied in these 
conjugates, octaarginine and penetratin without Met (penetratin(desMet), with or without 
tetrapeptide spacer (GFLG). From these compounds MTX might be released only after the 
degradation of peptide and/or the enzymatic cleavage of GFLG spacer. As the GFLG spacer 
can be cleaved by Cathepsin B lysosomal enzyme both the degradation and the enzyme 
cleavage can occur in case of vesicular transport, but not in case of direct translocation. 
Therefore the activity of the MTX and MTX-Glu5 conjugates mainly depends on the 
internalisation properties and inhibitory activity of the conjugates. 
The in vitro cytostatic effect of the conjugates was measured on resistant and sensitive breast 
cancer cell lines; MDA-MB-231 and MCF-7 cells, respectively. The MTX was active only on 
MCF-7 cells and did not show any activity on the resistant cell culture. The effect of cell-
penetrating peptides on the cytostatic activity was very divergent. Only the penetratin 
derivatives exhibited activity. Although the activity of this conjugate was lower on MCF-7 
cells compared to the free MTX, it was effective against MDA-MB-231 cells too. The 
reduction of the efficiency of MTX in the conjugates could be explained by the limited 
inhibition of the target enzymes by the conjugated forms. Earlier studies reported that 
conjugation with different carrier molecules decreased the enzyme inhibitory activity of MTX 
[25,31]. The alteration of the efficacy of octaarginine and penetratin(desMet) conjugates 
cannot be explained with the different internalisation ability of the cell-penetrating peptides. 
However, octaarginine efficiently penetrate into both cell lines (Figure 2), it has no in vitro 
cytostatic activity (Table 2). According to this observation, it was supposed that the 
internalised octaarginine conjugates cannot inhibit the target intracellular enzymes as much as 
the penetratin(desMet) ones. For studying if the mechanism of internalisation may cause this 
difference, enzyme labile spacer was introduced between the MTX and the CPP. The GFLG 
tetrapeptide spacer applied can be cleaved by cathepsin B enzyme in the lysosomes. Thus if 
the cells take up the conjugates by any kind of vesicular transport, the cleavage of this spacer 
may enhance the activity of the compound. While the presence of this spacer slightly 
increased the effect of penetratin(desMet) conjugate, it is significantly increased the activity 
of octaarginine conjugate. Based on these findings we suppose that a) the octaarginine 
conjugate mainly penetrate into the cells by vesicular transport, which is accordance with 
published data about the internalisation of oligoarginines [47] and/or b) the release of MTX 
from the conjugate is necessary.  
In case of the conjugates of MTX-Glu5, the octaarginine containing one had again no activity 
on MCF-7 and MDA-MB-231 cells. The penetratin(desMet) based conjugate was very active 
on resistant cells, but was inactive on sensitive cells. The effect of this conjugate was higher 
than that of the free MTX on sensitive cells. The presence of pentaglutamyl moiety in the 
conjugates reduces dramatically the internalisation of CPP’s on both cell lines. This reduction 
was more pronounced in case of the octaarginine construct. Our data are in accord with earlier 
data describing that the positively charged guanidine groups are essential in the internalisation 
of oligoarginines [48]. The negatively charged glutamic acid residues which could be close to 
the positively charged guanidine groups can establish electrostatic interaction and thus 
prevent the binding of cell-penetrating peptide to the cell membrane. This interpretation could 
be supported with the class of “activatable cell-penetrating peptides” [49]. In these constructs 
poly anionic peptide domains (mainly Glun) can inhibit the internalisation of poly cationic 
oligoarginines via electrostatic interaction. Removal of this inhibitory domain results in 
increased cellular uptake. The results of the cellular-uptake study published [50] showed that 
the arginines are important in the internalisation of penetratin(desMet), but their possible 
blocking in our constructs do not diminish fully the uptake. The effect of penetratin(desMet) 
conjugates on viability was more marked in the case of resistant MDA-MB-231 cells. While 
penetratin(desMet) can internalise at the similar extent into both cells, the cellular-uptake of 
pentaglutamylated derivative by resistant cells was smaller. The difference between the in 
vitro cytostatic activities of the two sets of conjugates may be explained with the altered 
mechanism of cellular uptake and/or with the altered enzyme sets present in the two cell lines. 
Based on the fluorescence intensity of the cells only the internalised amount of conjugates 
was measured, but the mechanism of the penetratin(desMet) translocation needs further 
investigations, considering that the mechanism of uptake can influence the intracellular 
distribution of the conjugates (cytosol vs vesicles) and thus the interactions with intracellular 
target enzymes. The altered mechanism may be responsible for the divergent in vitro 
cytostatic activity. However, to best of our knowledge there are no data in the literature about 
the cell-line dependent internalisation mechanism of cell-penetrating peptides. The other 
possible explanation of differences may be due to the altered enzyme set of different cells, 
and the differential binding ability of conjugates to these enzymes. 
The unwanted interaction of pentaglutamyl moiety with the positively charged cell-
penetrating peptides may cause the ineffectiveness of conjugates. Therefore the effect of 
spacer was also studied. This spacer increases the distance between the positively and 
negatively charged peptide domains and therefore may inhibit their unwanted interaction. 
Besides this, the GFLG tetrapeptide used as an enzyme labile spacer may increase the 
intracellular release of pentaglutamylated-MTX. The presence of GFLG spacer resulted in 
very effective penetratin conjugates on MCF-7 cells, but had no effect on the activity of 
MTX-Glu5 conjugates on MDA-MB-231 cells. The activity of this conjugate was similar to 
that of the free MTX. In case of MTX the insertion of the spacer improved the activity of 
octaarginine conjugate, but the MTX-Glu5-GFLG-Arg8 conjugate was fully ineffective. As the 
cytostatic activity of penetratin(desMet) conjugate was drastically enhanced by the insertion 
of GFLG spacer on MCF-7 cells, we can suppose that the release of MTX-Glu5 after 
cathepsin B cleavage contributed to the higher effect on the activity. The lack of its influence 
in octaarginine conjugate may mean that the cellular uptake is very inefficient to produce 
effective MTX-Glu5 concentration. To support these, the investigation of Cathepsin B enzyme 
cleavage of conjugates is planned. Based on the results and the inhibitory activity of 
conjugates and fragments on DHFR enzyme activity the smallest active compounds will be 
identified. Thus, at the moment it is early to propose even a hypothesis about the mechanism 
of action and structure-activity relationship. However, we are convinced that the observation 
presented in this paper is novel and important to communicate. 
Our results presented here demonstrate that the delivery of polyglutamylated MTX into tumor 
cells could result in pronounced improvement on the cytostatic effect on tumor cells in vitro. 
These data also highlight that the choice of cell-penetrating peptide and the design of the 
conjugate are important, since the selected CPP may have marked influence on the activity. 
Taking into consideration the possible limitations of CPP in in vivo measurements for 
example degradability, toxicity, further studies are planned to prove the potency of 
conjugate(s) presented as lead molecules in vivo. 
 
Conclusions 
 
The resistance of tumor cells against antitumor drugs is a growing problem in the cancer 
therapy. Therefore new drugs and/or the modification of existing ones circumventing the drug 
resistance is an intensively researched area. MTX is an effective antitumor compound, but the 
evolved drug resistance often hampers its use. In many cases the inefficient internalisation or 
polyglutamation could be responsible for the drug resistance. In this paper we described a new 
set of conjugates of MTX and its pentaglutamylated derivative (MTX-Glu5) combined with 
cell-penetrating peptide – octaarginine and penetratin(desMet). Although both cell-penetrating 
peptides were successfully used to deliver antitumor drug into cells, as reported in the 
literature, our results indicate that the penetratin(desMet) conjugates were more effective than 
the respective octaarginine conjugates under in vitro conditions. The delivery of MTX into 
cells was effective against MTX resistant MDA-MB-231 cells. The penetratin(desMet) 
conjugates containing MTX-Glu5 had the same activity on resistant cells than the free MTX 
on sensitive cells. The MTX-Glu5-Penetartin(desMet) and MTX-Glu5-GFLG-
Penetratin(desMet) conjugates were very active against resistant tumor cells, and the MTX-
Glu5-GFLG-Penetratin(desMet) had also increased efficacy against sensitive cells. Our results 
suggest that the delivery of polyglutamylated MTX by cell-penetrating peptide may reopen 
the way of the effective treatment of tumors. The activity of conjugates also highlights that 
although the internalisation of cell-penetrating peptide is very similar, the small differences 
may cause significantly altered activity. 
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